Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pevonedistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 known ✓ | Q13564 | 18/20 | 1.00 |
| ▸ | UBA3 known ✓ | Q8TBC4 | 16/20 | 1.00 |
| ▸ | UBA6 | A0AVT1 | 3/20 | 1.00 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | GRK5 | P34947 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | NEDD8 | Q15843 | 1/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 1.00 |
| ▸ | ATG7 | O95352 | 1/20 | 0.58 |
| ▸ | UBA7 | P41226 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pevonedistat SCHEMBL14321349 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL10016613 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL10048256 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL14328898 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL15685348 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL23833815 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL1800436 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL20603286 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL22472958 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL192291 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | LINK THERAPEUTICS, LLC | 2025-10-07 | — | — | US | disclosed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | INSR, IRS1, INSRR | NAE1 2314/4885UBA3 3149/4885UBA6 1732/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | NAE1 2111/4885UBA3 3055/4885UBA6 1829/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | NAE1 2314/4885UBA3 3149/4885UBA6 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.